LoginRegister

    Cadila Healthcare gets 14 USFDA observations for Moraiya plant

    Farhat NasimWritten by Farhat Nasim   |  

    The US Food and Drug Administration (USFDA) inspected the plant from April 22, 2019 to May 3, 2019, Cadila Healthcare said in a regulatory filing.


    New Delhi: Drug firm Cadila Healthcare Friday said the US health regulator has issued 14 observations after inspecting its manufacturing facility at Moraiya in Ahmedabad.


    The US Food and Drug Administration (USFDA) inspected the plant from April 22, 2019 to May 3, 2019, the company said in a regulatory filing.


    "The inspection concluded with 14 observations. There were no repeat observations or data integrity related observations," it added.







    AhmedabadCadilaCadila Healthcarecadila moraiya plantCadila PharmaceuticalsData IntegrityHealthcaremanufacturing facilityMoraiyaMoraiya facilitypharmapharma newspharma news indiaRamanbhai PatelUnited StatesUSFDAzydusZydus Cadila
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X